Cost-Effectiveness Analysis of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib for Inoperable or Recurrent Breast Cancer.

Toshihiro ShidaMotoko KanekoJiro OguraHiroki SawadaShiro HatakeyamaIchiro ArakawaHiroaki YamaguchiTadao Inoue

Published in: Gan to kagaku ryoho. Cancer & chemotherapy (2023)

The palbociclib and fulvestrant therapy provided better health outcomes than conventional fulvestrant monotherapy, but were costly and suggested to be less cost-effective.

Keyphrases

metastatic breast cancer
cell cycle
combination therapy
locally advanced
randomized controlled trial
squamous cell carcinoma
mesenchymal stem cells
cell cycle arrest
young adults
cell death
study protocol